โšกYour ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

Sponsored by University of Illinois at Chicago

Quick Self-Assessment

See if you qualify and express your interest

Preparing your pre-screening questions...

Current Status

Recruiting

Auto-verified from ClinicalTrials.gov

Verified Dec 16, 2025

Phase

Clinical Trial

Sponsor

University of Illinois at Chicago

Enrollment Target

38

Start Date

Sep 2023

๐Ÿ“Š
1 of 38 participants interested
3% interest

Express Your Interest Today

Interested in learning more? Complete the form below.

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Advance Medical Science

    Contribute to groundbreaking research

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel (varies by study)

  • Help Others

    Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3In-person assessment if eligible
  4. 4Begin participation

About This Study

The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of allogeneic bone marrow-derived MSCs in patients with nonhealing epitheliopathy (IRB Protocol 2020-0334). In the present study, we want to study the efficacy of this treatment on chronic epitheliopathies.

Who Can Participate

Inclusion Criteria

Visual Acuity:
Best corrected distance visual acuity (BCDVA) score โ‰ค 75 ETDRS letters, (โ‰ฅ 0.2 LogMAR, โ‰ค 20/32 Snellen or โ‰ค 0.625 decimal fraction) in the affected eye. Ocular Health:
Patients with non-resolving corneal epitheliopathy or epithelial defect after two or more weeks of standard non-surgical treatments (e.g., preservative-free artificial tears, gels or ointments; discontinuation of preserved topical drops; anti-inflammatory therapy, soft bandage contact lens).
No objective clinical evidence of improvement in the last 2 weeks (โ‰ค50% reduction in fluorescein staining or โ‰ค50% reduction in longest diameter of the epithelial defect).
If both eyes have chronic epithelial disease, the eye with the worse epithelial disease will be treated.
Evidence of impaired epithelial barrier manifested by fluorescein staining of the epithelium with a score 10 or higher by National Eye Institute grading.
Patients with stage 1 (no epithelial defect), stage 2 (per

โ“ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

๐Ÿ“‹

Study Type

INTERVENTIONAL

๐Ÿ‘ฅ

Target Enrollment

38 participants

โšง

Gender

ALL

๐Ÿข

Sponsor

University of Illinois at Chicago

Study Locations

Choose your preferred location or select flexible during enrollment

RECRUITING

Chicago

Illinois

Location available
View Chicago location page
RECRUITING

Baltimore

Maryland

Location available
View Baltimore location page
ACTIVE_NOT_RECRUITING

Boston

Massachusetts

Location available
View Boston location page
ACTIVE_NOT_RECRUITING

Philadelphia

Pennsylvania

Location available
View Philadelphia location page

Frequently Asked Questions

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

๐Ÿ”’ Secure ยท ๐Ÿฅ Expert Care

Find More Multiple Myeloma Trials by City

Browse all multiple myeloma clinical trials in these cities โ€” not just this study.

Looking for I cannot determine the primary medical condition from the provided information. The study title mentions mesenchymal stromal cells but doesn't specify what condition is being treated, and the conditions listed appear to be interventions rather than medical conditions. The brief summary field is empty/incomplete. Treatment in Chicago?

Join others in Illinois exploring innovative treatment options through clinical research

I cannot determine the primary medical condition from the provided information. The study title mentions mesenchymal stromal cells but doesn't specify what condition is being treated, and the conditions listed appear to be interventions rather than medical conditions. The brief summary field is empty/incomplete. Treatment Options in Chicago, Illinois

If you're searching for I cannot determine the primary medical condition from the provided information. The study title mentions mesenchymal stromal cells but doesn't specify what condition is being treated, and the conditions listed appear to be interventions rather than medical conditions. The brief summary field is empty/incomplete. treatment in Chicago, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Chicago, Baltimore, Boston and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with I cannot determine the primary medical condition from the provided information. The study title mentions mesenchymal stromal cells but doesn't specify what condition is being treated, and the conditions listed appear to be interventions rather than medical conditions. The brief summary field is empty/incomplete.. All study-related care is provided at no cost to participants.

Local Sites
3 locations in Illinois
Now Enrolling
Up to 38 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for I cannot determine the primary medical condition from the provided information. The study title mentions mesenchymal stromal cells but doesn't specify what condition is being treated, and the conditions listed appear to be interventions rather than medical conditions. The brief summary field is empty/incomplete.?

Potential Benefits

  • โœ“Access to new treatment approaches before public availability
  • โœ“Close monitoring by experienced medical professionals
  • โœ“Study-related care provided at no cost
  • โœ“Contribute to medical research for I cannot determine the primary medical condition from the provided information. The study title mentions mesenchymal stromal cells but doesn't specify what condition is being treated, and the conditions listed appear to be interventions rather than medical conditions. The brief summary field is empty/incomplete.

What to Expect

  • โ†’Initial screening to determine eligibility
  • โ†’Regular check-ups and monitoring visits
  • โ†’Possible compensation for time and travel
  • โ†’You can withdraw at any time

Frequently Asked Questions About This I cannot determine the primary medical condition from the provided information. The study title mentions mesenchymal stromal cells but doesn't specify what condition is being treated, and the conditions listed appear to be interventions rather than medical conditions. The brief summary field is empty/incomplete. Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT05705024. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.